

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

Damon Runyon Cancer Research Foundation

RRID:SCR_005106

Type: Tool

Proper Citation

Damon Runyon Cancer Research Foundation (RRID:SCR_005106)

Resource Information

URL: <http://www.damonrunyon.org/>

Proper Citation: Damon Runyon Cancer Research Foundation (RRID:SCR_005106)

Description: The Damon Runyon Cancer Research Foundation funds early career cancer researchers who have the energy, drive and creativity to become leading innovators in their fields. We identify the best young scientists in the nation and support them through four award programs: our Fellowship, Pediatric Cancer Fellowship, Clinical Investigator and Innovation Awards. Damon Runyon awards give young scientists: * Freedom to follow their own ideas, explore new paths and take risks * A prestigious endorsement that attracts further funding, advances their careers and accelerates their research * Guaranteed financial support, sparing them hours applying for grants Since 1946, Damon Runyon has invested more than \$240 million in the best young minds in the nation. Our alumni include 11 Nobel Laureates and leaders of major cancer centers across the United States. Many of our 3,300 scientists have gone on to make breakthroughs in the way we prevent, diagnose and treat many forms of cancer. The Damon Runyon Cancer Research Foundation is a registered nonprofit with 501(c)(3) status.

Abbreviations: Damon Runyon Foundation

Resource Type: institution

Keywords: fellowship, grant, cancer

Resource Name: Damon Runyon Cancer Research Foundation

Resource ID: SCR_005106

Alternate IDs: Crossref funder ID: 100001021, grid.453008.a, ISNI: 0000 0004 0508 2172, nlx_144117

Alternate URLs: <https://ror.org/01gd7b947>

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260912T195621+0000

Ratings and Alerts

No rating or validation information has been found for Damon Runyon Cancer Research Foundation.

No alerts have been found for Damon Runyon Cancer Research Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 67 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yaniv Z, et al. (2026) The IBEX knowledge-base a community resource enabling adoption and development of immunofluorescence imaging methods. eLife, 14.

Pratyush MR, et al. (2026) Label-free microscopy enables high-throughput identification of genes controlling biofilm development. mBio, 17(6), e0044826.

Liu Y, et al. (2026) DNA O-MAP uncovers the molecular neighborhoods associated with specific genomic loci. eLife, 13.

Nelson AN, et al. (2025) STAT1-mediated interferon signaling in the hematopoietic system is essential for restricting Usutu virus infection in vivo. PLoS neglected tropical diseases, 19(7), e0013317.

Schwoerer MP, et al. (2025) Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells. PLoS pathogens, 21(9), e1013412.

Nguyen E, et al. (2025) A small periplasmic protein governs broad physiological adaptations in *Vibrio cholerae* via regulation of the DbfRS two-component system. Nature communications, 16(1), 11230.

Pratyush MR, et al. (2025) Label-free microscopy enables high-throughput identification of genes controlling biofilm development. bioRxiv : the preprint server for biology.

Roberge N, et al. (2025) Twitching motility suppressors reveal a role for FimX in type IV pilus extension dynamics. PLoS genetics, 21(10), e1011802.

Nguyen E, et al. (2025) A small periplasmic protein governs broad physiological adaptations in *Vibrio cholerae* via regulation of the DbfRS two-component system. bioRxiv : the preprint server for biology.

Prentice JA, et al. (2024) Biofilm dispersal patterns revealed using far-red fluorogenic probes. *PLoS biology*, 22(11), e3002928.

Greaney AJ, et al. (2022) The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. *bioRxiv : the preprint server for biology*.

Greaney AJ, et al. (2022) A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. *PLoS pathogens*, 18(2), e1010248.

Greaney AJ, et al. (2022) The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. *PLoS pathogens*, 18(6), e1010592.

van Duinen AJ, et al. (2021) Catastrophic expenditure and impoverishment after caesarean section in Sierra Leone: An evaluation of the free health care initiative. *PloS one*, 16(10), e0258532.

Ehrenberg AJ, et al. (2021) Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus. *PloS one*, 16(5), e0251296.

Zinshteyn B, et al. (2021) Translational repression of NMD targets by GIGYF2 and EIF4E2. *PLoS genetics*, 17(10), e1009813.

Chang CH, et al. (2019) Islands of retroelements are major components of *Drosophila* centromeres. *PLoS biology*, 17(5), e3000241.

Muller M, et al. (2017) Nuclease escape elements protect messenger RNA against cleavage by multiple viral endonucleases. *PLoS pathogens*, 13(8), e1006593.

Park HB, et al. (2016) Pyrazinone protease inhibitor metabolites from *Photorhabdus luminescens*. *The Journal of antibiotics*, 69(8), 616.

Iwasaki S, et al. (2016) Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. *Nature*, 534(7608), 558.